• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA Hydrolase.可溶性环氧化物水解酶和脂磷壁酸水解酶双重抑制剂的设计
ACS Med Chem Lett. 2019 Oct 30;11(3):298-302. doi: 10.1021/acsmedchemlett.9b00330. eCollection 2020 Mar 12.
2
Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.白三烯A4水解酶/氨肽酶的双重抗炎及选择性抑制机制:基于比较分子动力学和结合自由能分析的见解
J Biomol Struct Dyn. 2016 Nov;34(11):2418-33. doi: 10.1080/07391102.2015.1117991. Epub 2016 Jan 11.
3
Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.设计高效氨肽酶非选择性白三烯 A4 水解酶抑制剂的可行性和生理学相关性。
Sci Rep. 2017 Oct 19;7(1):13591. doi: 10.1038/s41598-017-13490-1.
4
Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.用于设计可溶性环氧化物水解酶和白三烯A4水解酶双重抑制剂的计算机辅助片段生长策略
ACS Med Chem Lett. 2020 Apr 8;11(6):1244-1249. doi: 10.1021/acsmedchemlett.0c00102. eCollection 2020 Jun 11.
5
Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase.双 5-脂氧合酶激活蛋白和可溶性环氧化物水解酶抑制剂 diflapolin 的药理学特性和体内功效。
Sci Rep. 2017 Aug 24;7(1):9398. doi: 10.1038/s41598-017-09795-w.
6
Capturing LTA hydrolase in action: Insights to the chemistry and dynamics of chemotactic LTB synthesis.捕捉 LTA 水解酶的作用:对趋化性 LTB 合成的化学和动力学的深入了解。
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9689-9694. doi: 10.1073/pnas.1710850114. Epub 2017 Aug 21.
7
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.对脂肪酸酰胺水解酶具有双重活性的可溶性环氧化物水解酶抑制剂的鉴定与优化。
Bioorg Med Chem Lett. 2018 Feb 15;28(4):762-768. doi: 10.1016/j.bmcl.2018.01.003. Epub 2018 Jan 4.
8
Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.基于结构的药效团模型和分子对接技术鉴定人白三烯 A4 水解酶抑制剂。
Molecules. 2020 Jun 22;25(12):2871. doi: 10.3390/molecules25122871.
9
Development of Dual Inhibitors of Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase with Tetrazole Core.具有四氮唑核心的可溶性环氧水解酶/脂肪酸酰胺水解酶双重抑制剂的开发
Med Chem. 2023;19(10):1037-1048. doi: 10.2174/1573406419666230718152453.
10
Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.双可溶性环氧化物水解酶/脂肪酸酰胺水解酶抑制剂的设计与效能
ACS Omega. 2018 Oct 31;3(10):14076-14086. doi: 10.1021/acsomega.8b01625. Epub 2018 Oct 25.

引用本文的文献

1
Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19.通过可溶性环氧化物水解酶抑制剂激活内源性解决途径来管理 COVID-19。
Arch Pharm (Weinheim). 2022 Mar;355(3):e2100367. doi: 10.1002/ardp.202100367. Epub 2021 Nov 21.
2
Development and in vitro Profiling of Dual FXR/LTA4H Modulators.双重 FXR/LTA4H 调节剂的开发和体外特征分析。
ChemMedChem. 2021 Aug 5;16(15):2366-2374. doi: 10.1002/cmdc.202100118. Epub 2021 May 24.
3
Mitochondria Are Potential Targets for the Development of New Drugs Against Neutrophilic Inflammation in Severe Pneumonia Including COVID-19.线粒体是开发针对包括新冠肺炎在内的重症肺炎中性粒细胞炎症的新型药物的潜在靶点。
Front Pharmacol. 2021 Jan 29;12:609508. doi: 10.3389/fphar.2021.609508. eCollection 2021.
4
Systematic Assessment of Fragment Identification for Multitarget Drug Design.系统评估多靶标药物设计中的片段鉴定
ChemMedChem. 2021 Apr 8;16(7):1088-1092. doi: 10.1002/cmdc.202000858. Epub 2021 Feb 4.
5
Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.小分子可溶环氧化物水解酶抑制剂在炎症和癌症的多靶点和联合治疗中的应用。
Molecules. 2020 Nov 24;25(23):5488. doi: 10.3390/molecules25235488.
6
Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.基于结构的药效团模型和分子对接技术鉴定人白三烯 A4 水解酶抑制剂。
Molecules. 2020 Jun 22;25(12):2871. doi: 10.3390/molecules25122871.
7
Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.用于设计可溶性环氧化物水解酶和白三烯A4水解酶双重抑制剂的计算机辅助片段生长策略
ACS Med Chem Lett. 2020 Apr 8;11(6):1244-1249. doi: 10.1021/acsmedchemlett.0c00102. eCollection 2020 Jun 11.

本文引用的文献

1
Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome.靶向促炎和促修复脂质代谢组的生物合成网络。
FASEB J. 2019 May;33(5):6140-6153. doi: 10.1096/fj.201802509R. Epub 2019 Feb 8.
2
Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity.具有可溶性环氧化物水解酶抑制活性的多靶点药物的研发。
Prostaglandins Other Lipid Mediat. 2019 Feb;140:31-39. doi: 10.1016/j.prostaglandins.2018.12.003. Epub 2018 Dec 26.
3
Discovery of polar spirocyclic orally bioavailable urea inhibitors of soluble epoxide hydrolase.发现可口服的极性螺环型尿素类可溶性环氧化物水解酶抑制剂。
Bioorg Chem. 2018 Oct;80:655-667. doi: 10.1016/j.bioorg.2018.07.014. Epub 2018 Jul 17.
4
Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.基于设计的多药理学:药物化学家对多靶标化合物的看法。
J Med Chem. 2019 Jan 24;62(2):420-444. doi: 10.1021/acs.jmedchem.8b00760. Epub 2018 Aug 3.
5
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.对脂肪酸酰胺水解酶具有双重活性的可溶性环氧化物水解酶抑制剂的鉴定与优化。
Bioorg Med Chem Lett. 2018 Feb 15;28(4):762-768. doi: 10.1016/j.bmcl.2018.01.003. Epub 2018 Jan 4.
6
Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.设计高效氨肽酶非选择性白三烯 A4 水解酶抑制剂的可行性和生理学相关性。
Sci Rep. 2017 Oct 19;7(1):13591. doi: 10.1038/s41598-017-13490-1.
7
Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase.双 5-脂氧合酶激活蛋白和可溶性环氧化物水解酶抑制剂 diflapolin 的药理学特性和体内功效。
Sci Rep. 2017 Aug 24;7(1):9398. doi: 10.1038/s41598-017-09795-w.
8
Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.可溶性环氧化物水解酶作为治疗疼痛、炎症和神经退行性疾病的靶点。
Pharmacol Ther. 2017 Dec;180:62-76. doi: 10.1016/j.pharmthera.2017.06.006. Epub 2017 Jun 19.
9
Thermodynamic properties of leukotriene A hydrolase inhibitors.白三烯A水解酶抑制剂的热力学性质
Bioorg Med Chem. 2016 Nov 1;24(21):5243-5248. doi: 10.1016/j.bmc.2016.08.047. Epub 2016 Aug 26.
10
PENG: a neural gas-based approach for pharmacophore elucidation. method design, validation, and virtual screening for novel ligands of LTA4H.彭:一种基于神经气体的药效团阐释方法。LTA4H新型配体的方法设计、验证及虚拟筛选。
J Chem Inf Model. 2015 Feb 23;55(2):284-93. doi: 10.1021/ci500618u. Epub 2015 Feb 9.

可溶性环氧化物水解酶和脂磷壁酸水解酶双重抑制剂的设计

Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA Hydrolase.

作者信息

Hiesinger Kerstin, Schott Annika, Kramer Jan S, Blöcher René, Witt Finja, Wittmann Sandra K, Steinhilber Dieter, Pogoryelov Denys, Gerstmeier Jana, Werz Oliver, Proschak Ewgenij

机构信息

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Strasse 9, 60438 Frankfurt, Germany.

Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University Jena, Philosophenweg 14, 07743 Jena, Germany.

出版信息

ACS Med Chem Lett. 2019 Oct 30;11(3):298-302. doi: 10.1021/acsmedchemlett.9b00330. eCollection 2020 Mar 12.

DOI:10.1021/acsmedchemlett.9b00330
PMID:32184960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7073873/
Abstract

Multitarget anti-inflammatory drugs interfering with the arachidonic acid cascade exhibit superior efficacy. In this study, a prototype dual inhibitor of soluble epoxide hydrolase (sEH) and LTA hydrolase (LTAH) with submicromolar activity toward both targets has been designed and synthesized. Preliminary structure-activity relationship studies were performed to identify optimal substitution patterns. X-ray structure analysis of a promising dual inhibitor in complex with sEH, as well as molecular docking with LTAH provided a rationale for further optimization. Hereby, scaffold extension was successfully applied to yield potent dual sEH/LTAH inhibitors. The spectrum of pro- and anti-inflammatory lipid mediators was evaluated in M1 and M2 macrophages, stimulated with LPS, and incubated with the most promising compound . The effect of on the inflammatory lipid mediator profile characterizes dual sEH/LTAH inhibitors as an interesting option for future anti-inflammatory agent investigations.

摘要

干扰花生四烯酸级联反应的多靶点抗炎药物具有卓越的疗效。在本研究中,设计并合成了一种对可溶性环氧化物水解酶(sEH)和LTA水解酶(LTAH)均具有亚微摩尔活性的双靶点抑制剂原型。开展了初步的构效关系研究以确定最佳取代模式。对一种有前景的双靶点抑制剂与sEH的复合物进行X射线结构分析,并与LTAH进行分子对接,为进一步优化提供了理论依据。据此,成功应用骨架扩展法得到了强效的sEH/LTAH双靶点抑制剂。在用脂多糖刺激并与最有前景的化合物孵育的M1和M2巨噬细胞中评估了促炎和抗炎脂质介质的谱。该化合物对炎症脂质介质谱的影响表明,sEH/LTAH双靶点抑制剂是未来抗炎药物研究的一个有趣选择。